Global Mycoplasma Testing Market – Industry Trends and Forecast to 2030

 Mycoplasma Testing Market Analysis and Size

According to the CDC, the number of deaths from chronic lower respiratory diseases will be 152,657 in 2021. The number of deaths from respiratory illnesses, pulmonary disease, and tuberculosis has increased, and these figures are expected to rise further in the coming years, fuelling the growth of the mycoplasma testing market. Furthermore, key market participants anticipate an increase in demand for improved diagnostics for non-pulmonary therapies, which will drive the global market in the near future.

Data Bridge Market Research analyses that the mycoplasma testing market value is USD 295.06 million in 2022, is expected to reach USD 526.23 million by 2030, at a CAGR of 7.5% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Mycoplasma Testing Market Scope and Segmentation  

Market Definition

A mycoplasma test detects active or recent mycoplasma infections, bacterial infections. Testing can be done in a variety of ways depending on which one is suspected because there are different types of mycoplasma infections. M. pneumoniae, the most common Mycoplasma, causes upper respiratory infections and can be tested with a blood sample. Other mycoplasma tests may require the collection of a variety of samples, including sputum, joint fluid, body fluids, tissue samples, or a genital swab.

Mycoplasma Testing Market Dynamics

Drivers

• Increasing R&D investments

Rising research costs and increased R&D investments by key companies will almost certainly encourage companies to use highly efficient mycoplasma testing tools. For instance, Bristol-Myers Squibb began investing in developing investigational medicines to support clinical trials. Furthermore, with the introduction of biosimilars and the resulting lucrative R&D investment, safety testing has become critical to ensure that a product meets the standards for efficacy, safety, and overall public health. Merck KGaA expanded its manufacturing footprint in the United States in December 2020, investing more than USD 45.6 million (EUR 40 million) in Massachusetts and New Hampshire production facilities. The facilities were built to produce a wide range of biopharmaceutical manufacturing products while also increasing the company's production capacity. This is expected to improve the mycoplasma testing market.

• Innovative approaches and significant investments

As a result of innovative approaches and significant investments by operating players, the mycoplasma testing market is gaining traction. For instance, biologics accounted for seven of the top ten best-selling drugs in early 2020. This reflects the emergence of biologics in the global market. Cell lines are essential in the production of a wide range of biologic products, including monoclonal antibodies, viral vaccines, and cytokines, which are used for medicinal or therapeutic purposes. Mycoplasma strains greatly impact cell line metabolism, physiology, and gene expression. As a result, these are the certain factors which propel the mycoplasma testing market growth.

Opportunities

• Globalization of clinical trials

The primary reasons pharmaceutical and biopharmaceutical companies choose to outsource clinical trials and R&D are cost efficiency, ease of patient recruitment, lower operating costs and less stringent regulatory frameworks than those found in the United States and Western Europe. Aside from cost savings, sponsors cite improved quality and reduced time to market as key reasons for outsourcing business functions to CROs, CDMOs, and CMOs.

Restraints/Challenges

• High cost of instruments

The high cost of instruments and the lengthy and laborious detection process are expected to limit the growth of the mycoplasma testing market during the forecast period.

This mycoplasma testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the mycoplasma testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2020, Liofilchem S.r.l. introduced the AF Genital System, VTM, Lockable contact plates with improved microbial testing configuration. This product enhancement helped the company increase its revenue.
• In 2020, BioMérieux SA announced the availability of the biofire mycoplasma test for the detection of mycoplasma in biopharmaceutical products. This initiative aided the company in increasing the use of its products in the biotherapeutics market.

Global Mycoplasma Testing Market Scope

The mycoplasma testing market is segmented on the basis of technique, product, application, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Technique

• PCR
• ELISA
• Direct Assays
• Indirect Assays
• DNA Staining
• Microbial Culture Techniques
• Enzymatic

 Product

• Kits and Reagent
• PCR assays
• Nucleic acid detection kits
• Elimination kits
• Reagents
• Stains
• Standards
• Controls
• Others
• Instruments
• Others

 Application

• Cell Line Testing
• Virus Testing
• End-Of-Production Cell Testing
• Other

 End Users

• Hospitals
• Surgical Centers
• Clinics
• Community Healthcare
• Others

Distribution Channel

• Retail
• Direct Tenders

Mycoplasma Testing Market Regional Analysis/Insights

The mycoplasma testing market is analyzed and market size insights and trends are provided by country, technique, product, application, end users and distribution channel as referenced above.

The countries covered in the mycoplasma testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the mycoplasma testing market because of repeated purchases of consumables for the detection of mycoplasma in cell culture, the kits and reagents segment is expected to grow at the fastest rate during the forecast period of 2023 to 2030.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to increased demand for effective testing, the kits and reagents segment dominates the mycoplasma testing market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The mycoplasma testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for mycoplasma testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the mycoplasma testing market. The data is available for historic period 2011-2021.

Competitive Landscape and Mycoplasma Testing Market Share Analysis

The mycoplasma testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to mycoplasma testing market.

Some of the major players operating in the mycoplasma testing market are:

• AB ANALITICA s.r.l. (Italy)
• BIOMÉRIEUX (France)
• ELITechGroup (France)
• Liofilchem S.r.l. (Italy)
• Agilent Technologies, Inc. (U.S.)
• PromoCell GmbH (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• OSANG Healthcare (South Korea)
• Sacace Biotechnologies Srl (Italy)
• Lonza (Switzerland)
• Merck KGaA (Germany)
• Seegene Inc. (South Korea)
• Clongen Laboratories, LLC (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Charles River Laboratories (U.S.)
• Bionique Testing Laboratories LLC (U.S.)
• ZEAKON Diagnostics (India)

SKU-20216